A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

NCT06088017 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-03-27

No results posted yet for this study

Summary

A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-391(2)

Conditions

  • Dyslipidemias

Interventions

DRUG

CKD-391(2)

QD, PO

DRUG

CKD-331, D337

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2024-01-07
Completion
2024-01-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088017 on ClinicalTrials.gov